Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30

$10.64+0.02 (+0.19%)

Close on Nov 13, 2026Market cap $895.05MP/E –Yield –

Corvus Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Corvus Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?